Management

Steve Hoffman co-founded Tyme and has served as our Chief Executive Officer and Chairman since 2014. Mr. Hoffman has over 30 years of experience in biochemistry and physics, and has been the lead author on over 40 patents. For the last decade, he has focused on biopharmaceuticals for oncology, metabolic syndrome, and central nervous system disorders. Prior to working in biotech, he was involved in projects related to chemistry, aerospace and laser optics. In addition to leading the scientific development for his own companies, he has worked with multiple Fortune 500 healthcare companies, academic institutions, and the US government.

Ben Taylor has served as our President and Chief Financial Officer since 2017. Mr. Taylor has over 19 years of life sciences experience in investment banking and emerging growth companies. From 2016 to 2017, Mr. Taylor was Head of Commercial Pharma for Barclays Capital Inc. Prior to Barclays, Mr. Taylor spent ten years at Goldman, Sachs & Co., where he held a variety of roles, including Head of Emerging Pharma and Co-Head of Chinese and Southeast Asian Healthcare within the investment banking division. His career has primarily been focused on biopharmaceuticals, working as an advisor to over a hundred companies at various stages of development in more than 15 countries. Mr. Taylor received a Bachelor of Arts degree with honors in East Asian Studies from Brown University.

Dr. Giuseppe Del Priore has served as our Chief Medical Officer since 2016. From 2013 to 2016, Dr. Del Priore served as the National Director of Gynecologic Oncology for Cancer Treatment Centers of America (CTCA). Prior to CTCA, Dr. Del Priore was Professor and Director of Gynecologic Oncology at the Indiana University School of Medicine in Indianapolis, where he directed its gynecologic oncology fellowship program. He previously also served as Director of Gynecologic Oncology at New York Downtown Hospital, Montefiore Medical Center, and Bellevue Hospital in New York City, as well as Assistant Director of Gynecologic Oncology at New York University School of Medicine. He has served on several committees and organizations, including current appointments at the Society of Gynecologic Oncologists; and previously the Gynecologic Oncology Group, a National Cancer Institute Cooperative Group. He is also an examiner for the American Osteopathic Association Board of Obstetrics and Gynecology, Gynecologic Oncology subspecialty section. Dr. Del Priore earned his Doctor of Medicine with Distinction in Research from State University of New York Downstate Medical Center in Brooklyn. He studied at The City University of New York’s Brooklyn College in a combined Bachelor of Arts/Doctor of Medicine Program. Dr. Del Priore received a Master of Public Health in Biostatistics and Epidemiology from the University of Illinois at Chicago.

Jonathan Eckard has served as our Chief Scientific Affairs Officer since 2017 and assumed the role of Chief Business Officer in March 2019. Dr. Eckard has over 12 years of financial experience in equity research, bringing to us both important industry insights and comprehensive understanding of the healthcare equity capital markets. From 2016 to 2017, Dr. Eckard was Chief Business and Strategy Officer of SELLAS Life Science, a private oncology-focused biotechnology company. His previous finance roles include equity research analyst roles at Barclays Capital Markets, Citi Capital Markets, Leerink Swann, and HSBC Securities, where he primarily followed small to mid-sized biotechnology companies. Dr. Eckard received a Bachelor of Science degree in Biochemistry from Ohio University, a Master of Science degree in Toxicology and a PhD in Toxicology and Carcinogenesis from New York University School of Medicine.

Michele Korfin has served as our Chief Commercial Officer since October 2018 and assumed the role of Chief Operating Officer in March 2019. Ms. Korfin has over 20 years of experience in oncology, focused on product launches, oncology marketing strategy, commercial sales, market access and government affairs. From 2016 to July 2018, Ms. Korfin was Vice President of Market Access at Kite Pharma, where she oversaw the market access strategy, including payer relations, reimbursement and government affairs for Yescarta®, the first approved CAR-T therapy in lymphoma. Prior to joining Kite, Ms. Korfin spent more than a decade at Celgene in a variety of key strategic and operational roles, including head of the oncology sales force and overseeing the global development programs for REVLIMID® in lymphoma and CLL. She also led Celgene’s oncology sales force of over 120 representatives, responsible for $650 million in revenue for ABRAXANE®, which is now a standard of care in pancreatic cancer. Ms. Korfin has also held prior positions at Merck & Co as a manufacturing scientist, Bain & Company as a consultant and Schering-Plough in sales and marketing. Ms. Korfin holds an Master in Business Administration from Harvard Business School and a Bachelor of Science degree in Pharmacy from Rutgers University. She is also on the Board of Trustees of BioNJ, the organization that represents the biotechnology industry for New Jersey.

James Biehl has served as our Chief Legal Officer and Secretary since September 2018 and served on our board of directors from 2017 until September 2018. Mr. Biehl has over 29 years of experience as a corporate and securities lawyer representing big pharma, healthcare systems, healthcare consulting firms, and consumer products and medical device companies. His entire career was with the law firm of Drinker Biddle & Reath LLP where he joined the firm in 1989 and was a partner for over 20 years. Mr. Biehl received a Bachelor of Science degree in Industrial Management from Carnegie Mellon University and a Juris Doctor degree from Temple University Beasley School of Law.

Shabnam Stanicky has served as our Clinical Operations Officer since 2017. Ms. Stanicky has over 16 years of experience in oncology clinical research and experience in overseeing oncology field operations and global project management. From 2008 to 2017, Ms. Stanicky was a Clinical Operations Manager at Quintiles. Prior to joining Quintiles, she held positions of increasing responsibility at Eli Lilly and the John Wayne Cancer Institute. Ms. Stanicky received a Bachelor of Arts degree in Psychology from UCLA and a Master of Science degree in Health Care Management from California State University, Los Angeles.

Barbara Galaini has served as our Principal Accounting Officer since August 2018 and our Corporate Controller since April 2018. Ms. Galaini has over 25 years of experience in various finance positions in the financial services industry. From 2017 to April 2018, Ms. Galaini was the Chief Accounting Officer of the Americas for Avolon Holdings, a Dublin-based aircraft leasing company. Prior to 2017, she held various positions at CIT, including Chief Financial Officer and Controller of the Commercial Finance business segments, including the healthcare sector, and was the leader of the SEC Reporting Group. Ms. Galaini received a Bachelor of Science degree in Accounting and a Bachelor of Arts degree in American Studies and Economics from Rutgers University and is a Certified Public Accountant.

John Zucaro has served as our Senior Vice President – Manufacturing since 2013 and of Tyme’s precursor Luminant Biosciences LLC since 2011. Mr. Zucaro has over 25 years of experience in the pharmaceutical, chemical and defense industries serving in various roles for public, private and startup companies. Mr. Zucaro received a Bachelor of Science degree in Chemical Engineering from Drexel University, a Master of Science degree in Chemical Engineering from Villanova University, a Master in Business Administration in Finance from The Wharton School, University of Pennsylvania, and is a licensed Professional Engineer (Chemical).

Thomas Cook has served as our Vice President of Public Relations since 2014. Prior to joining us, Mr. Cook was the founder and Chief Executive Officer of Thomas Cook & Associates, a public relations firm based in Washington, DC. Mr. Cook brings decades of government relations experience as well as broad relationships with modern-day influencers, entertainers, and corporate executives. Mr. Cook has driven public relations efforts for some of his past clients, including US-Ireland Business Summit, the Leukemia Ball, Project Children, Vital Voices, the Holocaust Museum, the WWII Memorial Dedication, the Martin Luther King Jr. National Memorial, and the National Hospice Foundation. Mr. Cook serves on the Board of the Historical Society of Washington D.C., BMCC Tribeca Performing Arts Center, and Facing Addiction.